ELDN
Price
$3.28
Change
-$0.08 (-2.38%)
Updated
Apr 24, 02:18 PM (EDT)
Capitalization
202.4M
14 days until earnings call
SYRE
Price
$14.69
Change
+$0.47 (+3.31%)
Updated
Apr 24, 02:49 PM (EDT)
Capitalization
841.45M
14 days until earnings call
Ad is loading...

ELDN vs SYRE

Header iconELDN vs SYRE Comparison
Open Charts ELDN vs SYREBanner chart's image
Eledon Pharmaceuticals
Price$3.28
Change-$0.08 (-2.38%)
Volume$796
Capitalization202.4M
Spyre Therapeutics
Price$14.69
Change+$0.47 (+3.31%)
Volume$358
Capitalization841.45M
ELDN vs SYRE Comparison Chart
Loading...
ELDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELDN vs. SYRE commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELDN is a Hold and SYRE is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (ELDN: $3.35 vs. SYRE: $14.22)
Brand notoriety: ELDN and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELDN: 102% vs. SYRE: 83%
Market capitalization -- ELDN: $202.4M vs. SYRE: $841.45M
ELDN [@Biotechnology] is valued at $202.4M. SYRE’s [@Biotechnology] market capitalization is $841.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELDN’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • ELDN’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, ELDN is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELDN’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • ELDN’s TA Score: 4 bullish, 4 bearish.
  • SYRE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than ELDN.

Price Growth

ELDN (@Biotechnology) experienced а +11.67% price change this week, while SYRE (@Biotechnology) price change was +14.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.04%. For the same industry, the average monthly price growth was -8.89%, and the average quarterly price growth was -12.57%.

Reported Earning Dates

ELDN is expected to report earnings on Aug 07, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+8.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($841M) has a higher market cap than ELDN($202M). ELDN has higher P/E ratio than SYRE: ELDN (4.81) vs SYRE (1.72). ELDN YTD gains are higher at: -18.689 vs. SYRE (-38.918). ELDN has higher annual earnings (EBITDA): -55.85M vs. SYRE (-208.57M). SYRE has more cash in the bank: 603M vs. ELDN (78.2M). SYRE has less debt than ELDN: SYRE (0) vs ELDN (501K). ELDN (0) and SYRE (0) have equivalent revenues.
ELDNSYREELDN / SYRE
Capitalization202M841M24%
EBITDA-55.85M-208.57M27%
Gain YTD-18.689-38.91848%
P/E Ratio4.811.72280%
Revenue00-
Total Cash78.2M603M13%
Total Debt501K0-
FUNDAMENTALS RATINGS
ELDN vs SYRE: Fundamental Ratings
ELDN
SYRE
OUTLOOK RATING
1..100
178
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1795
PRICE GROWTH RATING
1..100
5093
P/E GROWTH RATING
1..100
7376
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ELDN's Valuation (43) in the Pharmaceuticals Major industry is somewhat better than the same rating for SYRE (76). This means that ELDN’s stock grew somewhat faster than SYRE’s over the last 12 months.

ELDN's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that ELDN’s stock grew similarly to SYRE’s over the last 12 months.

ELDN's SMR Rating (17) in the Pharmaceuticals Major industry is significantly better than the same rating for SYRE (95). This means that ELDN’s stock grew significantly faster than SYRE’s over the last 12 months.

ELDN's Price Growth Rating (50) in the Pharmaceuticals Major industry is somewhat better than the same rating for SYRE (93). This means that ELDN’s stock grew somewhat faster than SYRE’s over the last 12 months.

ELDN's P/E Growth Rating (73) in the Pharmaceuticals Major industry is in the same range as SYRE (76). This means that ELDN’s stock grew similarly to SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELDNSYRE
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
ELDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TGVFX42.74N/A
N/A
Touchstone Growth Opportunities A
MDPSX84.72N/A
N/A
ProFunds Mid Cap Svc
GPGOX3.11N/A
N/A
Grandeur Peak Global Opportunities Inv
BIGIX27.39N/A
N/A
William Blair International Growth I
HGOSX55.08N/A
N/A
Hartford Growth Opportunities R4

ELDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELDN has been loosely correlated with ATOS. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ELDN jumps, then ATOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELDN
1D Price
Change %
ELDN100%
-0.89%
ATOS - ELDN
35%
Loosely correlated
+11.25%
ZURA - ELDN
35%
Loosely correlated
-3.36%
SYRE - ELDN
35%
Loosely correlated
+1.86%
CDXS - ELDN
35%
Loosely correlated
+1.79%
AMLX - ELDN
34%
Loosely correlated
+2.85%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with CGON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+1.86%
CGON - SYRE
53%
Loosely correlated
+1.22%
APGE - SYRE
52%
Loosely correlated
+2.93%
ACLX - SYRE
51%
Loosely correlated
+0.81%
PRME - SYRE
50%
Loosely correlated
+4.14%
IMNM - SYRE
50%
Loosely correlated
+3.54%
More